Onabotulinum Toxin A (BoNT-A) for Drooling in Children: A Systematic Review and Meta-Analysis.

Haresh OadAlix MaltezeanuSabrina Daniela da Silva Sam J Daniel

Published in: The Laryngoscope (2024)

BoNT-A is a clinically effective therapy that improves drooling severity in children with sialorrhea. Although there were some adverse side effects reported, they were transient and not severe. Future studies are needed to further evaluate the best techniques and to identify the ideal dosages required to achieve the optimal outcomes. Laryngoscope, 2024.

Keyphrases

young adults
escherichia coli
early onset
current status
stem cells
emergency department
adipose tissue
mesenchymal stem cells
drug induced
adverse drug
glycemic control